Application of combined medication of bacteroides fragilis and PD-1 and PD-L1 antibodies in treatment of respiratory system tumors

A Bacteroides fragilis, PD-L1 technology, applied in anti-tumor drugs, antibodies, drug combinations, etc., can solve the problem of no PD-1/PD-L1 antibody microecological preparations, etc., and improve the body's anti-tumor immune response. , the effect of prevention and treatment of respiratory system tumors

Pending Publication Date: 2022-04-15
GUANGZHOU ZHIYI PHARMA INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Although there is a good interaction between intestinal flora and PD-1/PD-L1 antibodies, there

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combined medication of bacteroides fragilis and PD-1 and PD-L1 antibodies in treatment of respiratory system tumors
  • Application of combined medication of bacteroides fragilis and PD-1 and PD-L1 antibodies in treatment of respiratory system tumors
  • Application of combined medication of bacteroides fragilis and PD-1 and PD-L1 antibodies in treatment of respiratory system tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Preparation of Bacteroides fragilis Live Bacteria Liquid and Inactivated Bacteria Liquid

[0050] Streak inoculation of Bacteroides fragilis ZY-312 strain on blood plate, anaerobic culture for 48h. Observe the colony morphological characteristics, staining characteristics, size, club shape and distribution, etc.

[0051] Colony characteristics: After Bacteroides fragilis ZY-312 was cultured on a blood plate at 37°C for 48 hours, it was slightly convex, translucent, white, smooth, non-hemolytic, and the diameter of the colony was between 1mm and 3mm. See figure 1 .

[0052] Morphology under the microscope: Bacteroides fragilis ZY-312 was examined by Gram staining. It is a Gram-negative bacterium with a typical rod shape, blunt rounded ends and dense staining. The uncolored part in the middle of the bacteria is like a vacuole. figure 2 .

[0053] A single colony was selected and inoculated in a plant-derived peptone liquid medium for fermentation and cultiva...

Embodiment 2

[0055] Example 2 Application of Bacteroides fragilis combined with PD-1 antibody in the treatment of non-small cell lung cancer

[0056] 1. Materials and methods

[0057] (1) Experimental grouping and dosing regimen

[0058] 70 BALB / c female mice were selected and randomly divided into 7 groups according to the body weight range, namely blank group, model group, ZY-312 group (10 10 CFU / monkey), PD-1 antibody (PD-1 ab) group (purchased from BioXcell, product number BE0146, the same below 200 μg / monkey), ZY-312 live bacteria combined with PD-1 antibody group (10 10 CFU / only), ZY-312 inactivated bacteria group (10 10 CFU / only), ZY-312 inactivated bacteria combined with PD-1 antibody group (10 10 CFU / only), 10 in each group. Except for the blank group, animals in other groups were injected with 1×10 6 LLC cells, tumor volume reaches 50-100mm 3 Dosing in groups was started at D0: starting from D0, animals in the blank group and the model group were orally administered 300 μL ...

Embodiment 3

[0101] Example 3 Application of Bacteroides fragilis combined with PD-L1 antibody in the treatment of non-small cell lung cancer

[0102] 1. Experimental design and process

[0103] Experimental design: 70 BALB / c female mice were selected and randomly divided into 7 groups according to body weight range, namely blank group, model group, ZY-312 group (10 10 CFU / monkey), PD-L1 antibody (PD-L1 ab) group (BE0101, BioXcell 200μg / bird), ZY-312 live bacteria combined with PD-L1 antibody group (10 10 CFU / only), ZY-312 inactivated bacteria group (10 10 CFU / only), ZY-312 inactivated bacteria combined with PD-L1 antibody group (10 10 CFU / only), 10 in each group. Except for the blank group, animals in other groups were injected with 1×10 6 LLC cells, tumor volume reaches 50-100mm 3 Dosing in groups was started at D0: starting from D0, animals in the blank group and model group were orally administered 300 μL of normal saline daily, and intraperitoneally injected with 200 μL of PBS on...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses bacteroides fragilis, in particular to combined application of bacteroides fragilis ZY-312 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.10685 and a PD-1 antibody and/or a PD-L1 antibody, and the bacteroides fragilis ZY-312 and the PD-1 antibody and/or the PD-L1 antibody are used for correcting the proportion of immune cells of a body, regulating the level of cancer-related cytokines of the body, improving the anti-tumor immune response of the body and effectively preventing and treating tumors of a respiratory system

Description

[0001] The microbial strains used in the implementation of the present invention have been preserved on April 2, 2015 at the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Management Committee (No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing). Taxonomic designation: Bacteroides fragilis ZY-312 (Bacteroides fragilis ZY-312), deposit number CGMCC No.10685. Bacteroides fragilis ZY-312 was isolated and obtained by the applicant unit of the present invention, and has been authorized for patent protection (patent number 201510459408.X). According to the provisions of the patent examination guidelines, the public can buy it from commercial channels or has authorized it without preservation, that is, No deposit certificate is required. technical field [0002] The present invention relates to an application technology of Bacteroides fragilis, in particular to the application of a combination of Bacteroides fragilis and PD-1 antibody or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/741A61K45/06A61K39/395A61P35/00
CPCY02A50/30A61K35/741A61K39/395A61K45/06A61P35/00C12N1/20C12R2001/01
Inventor 郑丽君易晓敏常秀娟林渝清
Owner GUANGZHOU ZHIYI PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap